Skip to main content
XRAYDENTSPLY SIRONA Inc.Sell4.8·$10.65
SellModerate Confidence
Investment thesis

Dentsply Sirona trades at a deeply discounted forward P/E of 6.6x with 32% analyst upside from current levels, but the business is in a confirmed downtrend, has missed earnings in 2 of the last 4 quarters, and carries an elevated put-to-call ratio of 8.50 that signals heightened institutional hedging activity.

Thesis pillars

  • Deep Value Versus Earnings Deterioration↓Deteriorating
  • Strong Piotroski Quality Backbone→Stable
  • Earnings Miss Pattern Downtrend↓Deteriorating
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days

Full reasoning →

Open full analysis

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis

Recovery setup

SellVALUE-TRAP 1/5ValueShortModerate Confidence

Healthcare · Medical Instruments & Supplies

Earnings today — results expected after close (2026-11-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $10.65: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 17%; Below-average business quality; Below long-term trend.

DENTSPLY SIRONA Inc. manufactures professional dental products across four segments — Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare — sold in approximately 140 countries. About two-thirds of dental... Read more

$10.65+4.8% A.UpsideScore 4.8/10#26 of 29 Medical Instruments & Supplies
QualityF-score6 / 9FCF yield6.67%
Stop $9.90Analyst target $11.16(−10% haircut)A.R:R 0.3:1
Analyst consensus$12.40+16.4%15 analysts with price targets
$11.16Analyst target
$10.65price
$12.40mean
$9
$17

Sell if holding. Engine safety override at $10.65: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 17%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 75. Score 4.8/10, moderate confidence.

Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: aggressive.

10-K grounded · weekly refresh

About DENTSPLY SIRONA Inc.

About DENTSPLY SIRONA Inc.

Dentsply Sirona's four reportable segments — Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare — encompass products including CEREC same-day restoration systems, the SureSmile clear aligner platform, and dental implant and continence care lines sold in approximately 140 countries. Henry Schein, Inc. represented 13% of net sales in 2025, making it the largest single distributor in a network through which roughly two-thirds of dental products flow. The company plans to increase R&D investment from approximately 4% to 5% of net sales beginning in 2026.

Dentsply Sirona earns revenue across all four operating segments. Connected Technology Solutions sells imaging equipment, treatment centers, CAD/CAM systems — primarily CEREC, which enables same-day restorations — and Primescan 2 intraoral scanners integrating with the cloud-based DS Core platform. Essential Dental Solutions provides endodontic files, sealers, composites, and preventive products to dental professionals. Orthodontic and Implant Solutions covers the SureSmile clear aligner platform, digital implant systems, and prosthetics. Wellspect Healthcare sells urinary catheters and bowel management systems primarily to medical supply distributors. The company generates a substantial portion of revenue through a limited number of distributors and is actively diversifying its U.S. distributor base beginning in 2026. Certain raw materials are sourced from single-source suppliers under agreements subject to periodic renewal; disruption of those sources could interrupt manufacturing.

Show full overview

EU Medical Device Regulation compliance is a named, dated regulatory obligation: Dentsply Sirona completed quality management system certifications in 2024, but Class III and implantable Class IIb devices must achieve EU MDR certification by December 31, 2027 and non-implantable Class IIb and lower-risk devices by December 31, 2028. A simultaneous execution risk is the 2026 restructuring plan — expected to incur $55 million to $65 million in charges and generate approximately $120 million in annualized savings — running concurrently with a multi-year global ERP system implementation begun in 2023. Cost overruns or delays in either program could adversely affect results of operations.

See also: Healthcare · Medical Instruments & Supplies

From DENTSPLY SIRONA Inc.'s most recent 10-K filing, extracted June 16, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Oct 28, 2026

Recent Developments — DENTSPLY SIRONA Inc.

Latest item Oct 28, 2026 · Generated 2026-11-05T12:04:10Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 2026Earnings today — results expected after close· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.5 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)7.2
Mkt Cap$2.1B
EV/EBITDA8.0
Profit Mgn-15.0%
ROE-33.0%
Rev Growth-4.1%
Beta0.86
DividendNone
Analysts with ratings23

Quality Signals

Piotroski F6/9

Options Flow

P/C0.10bullish
IV98%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Revenue shrinking — -4.1% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
1.5
Declining revenue: -4%
Low model confidence on this dimension (33%).

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.0
Support Resistance
0.5
Gap
4.0
52w Position
4.4

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.0
Quality Rank
0.7
Value Rank
9.6

Unprofitable operations — net margin -15.0%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Roa
1.3
Moat
3.2
Operating Margin
3.7
Fcf Quality
4.8
Gross Margin
5.9
Current Ratio
5.9
Piotroski F
6.7
FCF-positive but moderate margins (FCF margin 4%, FCF yield 6.7%)No competitive moat
GatesA.R:R 0.3 < 1.5@spotEARNINGS PROXIMITY 0d<=7dDeath cross (50MA < 200MA)Momentum 7.0>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
75 · Overbought
↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $8.32Resistance $10.76

Price Targets

$10
$11
A.Upside+4.8%
A.R:R0.3:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.5 < 4.0)
! asymmetry at 0.3 (below the engine's 1.5 threshold)@spot
! EARNINGS_PROXIMITY:0d<=7d

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-11-05 (Earnings today — results expected after close)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is XRAY stock a buy right now?

Sell if holding. Engine safety override at $10.65: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: High short interest: 17%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 75. Prior stop was $9.90. Score 4.8/10, moderate confidence.

What is the XRAY stock price target?

Analyst target: $11.16 (+4.8% upside). Prior stop was $9.90. Stop-loss: $9.90.

What are the risks of investing in XRAY?

Quality below floor (3.5 < 4.0).

Is XRAY overvalued or undervalued?

DENTSPLY SIRONA Inc. trades at a P/E of N/A (forward 7.2). TrendMatrix value score: 8.1/10. Verdict: Sell.

What do analysts say about XRAY?

23 analysts rate XRAY, with a consensus score of 3.5/5. 15 analysts publish price targets averaging $12.

What does DENTSPLY SIRONA Inc. do?DENTSPLY SIRONA Inc. manufactures professional dental products across four segments — Connected Technology Solutions,...

DENTSPLY SIRONA Inc. manufactures professional dental products across four segments — Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare — sold in approximately 140 countries. About two-thirds of dental consumable and technology products are distributed through third parties; Henry Schein, Inc. accounted for 13% of net sales in 2025.

Related stocks: STAA (STAAR Surgical Company) · NVST (Envista Holdings Corporation) · TFX (Teleflex Incorporated) · ALGN (Align Technology, Inc.) · MMED (MiniMed Group, Inc.)
Home › Stocks › XRAY

Latest news

Latest News

Fiscal.ai8d agoProduct
Fiscal.ai10d agoAnalyst
Benzinga10d ago
Benzinga10d ago
Benzinga14d agoAnalyst
Fiscal.ai16d agoEarnings
Benzinga22d agoAnalyst
Benzinga27d agoAnalyst
Benzinga29d agoProduct
Benzinga49d agoAnalyst
Benzinga73d agoAnalyst
Benzinga78d agoProduct
Benzinga91d agoEarnings
Benzinga91d ago
Benzinga99d agoAnalyst
Benzinga100d agoProduct
Benzinga119d ago
Benzinga147d agoLeadership Change
Benzinga160d agoAnalyst
Benzinga163d ago